Taking tamoxifen for ten years following breast cancer surgery rather than five is more effective and better at reducing the risk of recurrence and death, according to a recent trial led by Oxford University's Clinical Trial Service Unit (CTSU), called ATLAS. The findings, published online in The Lancet, explain how tamoxifen is able to suppress the effect that the female sex hormone estrogen has in causing estrogen receptor positive (ER-positive) breast cancer...
More...
More...